Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at BMO Capital Markets Prescription for Success Healthcare Conference Transcript

Jun 25, 2019 / 12:40PM GMT
Release Date Price: €157.48 (-0.77%)
Gary Jay Nachman
BMO Capital Markets Equity Research - Analyst

Hi, everyone. I'm Gary Nachman, the specialty pharma analyst at BMO. We're very excited to have Sage management with us, Al Robichaud, Chief Scientific Officer; and Kimi Iguchi, CFO. So we'll be able to cover all aspects of the pipeline with Al, even the early-stage programs and, of course, the commercial developments with the upcoming launch of ZULRESSO that Kimi will be able to address. So it's really great to have you guys here during this very exciting time for the company. I was just saying that Jeff is probably a little busy with the launch of the new products.

Kimi E. Iguchi
Sage Therapeutics, Inc. - CFO & Treasurer

Yes. Absolutely. The whole company.

Gary Jay Nachman
BMO Capital Markets Equity Research - Analyst

Good. We'll get to ZULRESSO after, of course, but let's start with SAGE-217, Al, where most of the investor focus has been. So looking ahead to the Phase III MDD study readout in either 4Q of this year or 1Q of next year. What are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot